275.00
+0.50
+(0.18%)
At close: 12:35:49 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,743,362.00
1,688,987.00
1,400,074.00
1,035,659.00
855,851.00
Cost of Revenue
314,367.00
284,097.00
207,274.00
141,212.00
154,648.00
Gross Profit
1,428,995.00
1,404,890.00
1,192,800.00
894,447.00
701,203.00
Operating Expense
515,461.00
510,095.00
425,194.00
526,834.00
371,264.00
Operating Income
913,534.00
894,795.00
767,606.00
367,613.00
329,939.00
Net Non Operating Interest Income Expense
10,757.00
10,262.00
4,806.00
556.00
-2,915.00
Pretax Income
945,341.00
909,392.00
777,178.00
357,486.00
337,759.00
Tax Provision
246,387.00
283,684.00
243,346.00
111,844.00
99,682.00
Net Income Common Stockholders
698,954.00
625,708.00
533,832.00
245,642.00
238,077.00
Diluted NI Available to Com Stockholders
698,954.00
625,708.00
533,832.00
245,642.00
238,077.00
Basic EPS
12.84
11.49
9.80
4.51
4.37
Diluted EPS
12.82
11.47
9.79
4.51
4.37
Basic Average Shares
54,463.00
54,463.00
54,463.00
54,463.00
54,463.00
Diluted Average Shares
54,523.75
54,535.00
54,539.00
54,524.00
54,536.00
Total Expenses
829,828.00
794,192.00
632,468.00
668,046.00
525,912.00
Net Income from Continuing & Discontinued Operation
698,954.00
625,708.00
533,832.00
245,642.00
238,077.00
Normalized Income
699,058.99
625,798.13
533,250.90
247,251.28
242,144.82
Interest Income
16,849.00
13,204.00
6,151.00
3,362.00
7,489.00
Interest Expense
6,092.00
2,942.00
1,345.00
2,806.00
2,915.00
Net Interest Income
10,757.00
10,262.00
4,806.00
556.00
-2,915.00
EBIT
951,433.00
912,334.00
778,523.00
360,292.00
340,674.00
EBITDA
1,046,220.00
985,161.00
836,673.00
416,055.00
374,478.00
Reconciled Cost of Revenue
314,367.00
284,097.00
207,274.00
141,212.00
154,648.00
Reconciled Depreciation
94,787.00
72,827.00
58,150.00
55,763.00
33,804.00
Net Income from Continuing Operation Net Minority Interest
698,954.00
625,708.00
533,832.00
245,642.00
238,077.00
Total Unusual Items Excluding Goodwill
-142.00
-131.00
846.00
-2,342.00
-5,771.00
Total Unusual Items
-142.00
-131.00
846.00
-2,342.00
-5,771.00
Normalized EBITDA
1,046,362.00
985,292.00
835,827.00
418,397.00
380,249.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-37.01
-40.87
264.90
-732.72
-1,703.18
12/31/2020 - 1/10/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1777.TWO SYN-TECH Chem. & Pharm. Co., Ltd.
92.10
+0.33%
6461.TWO Intech Biopharm Corporation
24.85
+0.20%
4192.TWO SynCore Biotechnology Co.,Ltd
33.40
-0.15%
4131.TWO NeoCore Technology Co., Ltd.
31.00
0.00%
3205.TWO Sagittarius Life Science Corp
33.95
-1.59%
4162.TWO PharmaEngine, Inc.
95.10
+2.15%
6919.TW CALIWAY BIOPHARMACEUTICALS CO L
665.00
+3.74%
6662.TWO BioLASCO Taiwan Co., Ltd.
33.00
-0.30%
8279.TWO Syngen Biotech Co.,Ltd.
124.50
0.00%
6617.TWO Gongwin Biopharm Holdings Co., Ltd.
112.00
-0.88%